Riskpilot← Back to searchSign inGet full accessÆskulapfonden
EFOActiveCVR 38059629Hagemannsvej 11Other social work activities without accommodation n.e.c. · NACE 8899Est. 2016— employees
Revenue 2025
—
EBITDA margin
—
-25% vs 2024
Equity ratio
99.9%
Financial strength
Net profit 2025
DKK 256K
-28% vs 2024
| Revenue | — | — |
| EBITDA | DKK 247K | -25% |
| Net profit | DKK 256K | -28% |
| Total assets | DKK 10,8M | +2% |
| Equity | DKK 10,8M | +2% |
| Employees | — | — |
Legal name
Æskulapfonden
CVR number
38059629
Legal form
Erhvervsdrivende fond
NACE code
8899 · Other social work activities without accommodation n.e.c.
Founded
10. juni 2016
Share capital
DKK 300.000
Employees
—
VAT registered
No
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Fonden tegnes af den samlede bestyrelse eller af formanden eller næstformanden i forening med to bestyrelsesmedlemmer.
Company purpose
Fondens formål er at besidde ejerandele i virksomheder, der udvikler, producerer og/forhandler antroposofisk og homøopatisk medicin samt andre helsebringende produkter, at støtte antroposofisk virksomheder - herunder specielt antroposofisk medicinsk forskning og oplysningsvirksomhed i Danmark, hvortil støtte kan gives i form af legater eller lån på særlige vilkår.
Address
Hagemannsvej 11
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -40 | -35 | 687 | 497 | 587 | 1.892 | 80 | 312 | 327 | 247 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -40 | -35 | 687 | 497 | 587 | 1.892 | 80 | 312 | 327 | 247 |
| Net financials | 1.700 | 4.520 | 708 | 527 | 603 | 1.945 | 156 | 359 | 395 | 309 |
| Profit before tax | 1.660 | 4.485 | 686 | 496 | 578 | 1.909 | 125 | 322 | 355 | 256 |
| Tax | -3 | -8 | -5 | -0 | -0 | 16 | -0 | -0 | -0 | -0 |
| Net profit | 1.664 | 4.492 | 691 | 496 | 578 | 1.893 | 125 | 322 | 355 | 256 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.979 | 6.474 | 7.157 | 7.518 | 8.096 | 9.943 | 10.020 | 10.262 | 10.617 | 10.843 |
| Equity | 1.964 | 6.456 | 7.147 | 7.508 | 8.086 | 9.933 | 10.010 | 10.252 | 10.607 | 10.833 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 15 | 18 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Total debt | 15 | 18 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
EBITDA margin
24660700.0%
This company
15.8%
Market median
+156080280% vs market
20162025
Equity ratio
99.9%
This company
38.2%
Market median
+162% vs market
20162025
Return on equity
2.4%
This company
18.4%
Market median
-87% vs market
20162025
Net profit margin
25621300.0%
This company
8.1%
Market median
+316312246% vs market
20162025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20162025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-06-10 – 2016-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Chairman | 2025 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2024 | — | — | |
| Deputy Chairman | 2017 | — | — | |
| Chairman | 2017 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2025 | — | — | |
| Deputy Chairman | 2016 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Æskulapfonden 
ALLERGICA A/SBoard members of Æskulapfonden also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Klaus Loehr-Petersen | Deputy Chairman | 0 companies |
| Jens-Otto Andersen | Board of Directors | 0 companies |
| Lars Pehrson | Chairman | 0 companies |
| Peer Bach Boesen | Deputy Chairman | 0 companies |
| Finn Madsen | Chairman | 0 companies |
| Tomas Ulrick Henckel Johansen | Board of Directors | 0 companies |
| Jesper Hollensberg | Board of Directors | 0 companies |
| Monica Nissen | Deputy Chairman | 0 companies |